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Abstract
Objective: Gross cystic disease (GCD) is the most common benign breast pathology. Although breast
cysts are not considered pre-malignant lesions, an increased risk of breast cancer has been reported
for patients with type I cysts ðNaþ=Kþ , 3Þ: Furthermore, an augmented IGF-I/IGF-binding protein-3
(IGFBP-3) ratio has been described in breast cancer patients. The objective was to evaluate serum
IGF-I and binding protein concentrations of type I and type II cyst patients as compared with
healthy women.
Methods: Twenty-four patients with type I cysts, 17 with type II cysts and 25 healthy women were
evaluated. Serum IGF-I, IGFBP-3 and IGFBP-1 concentrations were measured by IRMA.
Results: IGF-I concentrations were significantly higher in sera from patients with type I cysts than in
patients with type II cysts. A highly significant decrease of IGFBP-3, the major IGFBP, was found in
patients with type I cysts with respect to healthy women, whereas no significant difference was
evident between the different cyst types. The IGF-I/IGFBP-3 ratio, an estimate of biologically active
IGF-I, was very significantly higher in patients with type I cysts than in both type II patients and
healthy women. IGFBP-1 levels were significantly lower in patients with type I than in controls
and type II cysts. The IGF-I/IGFBP-1 ratio was significantly higher in patients with type I cysts
than in type II bearers and healthy women. Estrogen levels correlated with IGF-I in patients
and controls.
Conclusions: The enhanced levels of IGF-I/IGFBP-3 found in patients with type I cysts could eventually
be associated with the increased risk of breast cancer described for this group.
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Introduction
Gross cystic disease (GCD) is the most common benign
breast pathology. It has been reported that about 7%
of women in Western countries develop a palpable
cyst (1). The breast cysts originate from the terminal
duct lobular units of the breast, which are also the
site of origin of most proliferative breast lesions,
including ductal and lobular in situ carcinoma (2).
The composition of breast cyst fluid (BCF) has been
studied for the last 20 years (3, 4). A differential distri-
bution of electrolytes, steroid and peptide hormones and
growth factors has been found (5), suggesting that
mammary cysts are complex endocrine entities capable
of accumulating and probably synthesizing certain
hormones (6). There are two clearly defined types of
breast cysts. Type I cysts are lined by apocrine
epithelium and contain fluid with an electrolyte
composition similar to that of intracellular fluid (high
concentrations of potassium (K+), low concentrations
of sodium (Na+), a Na+/K+ ratio ,3, and high concen-
trations of conjugated steroid hormones and epidermal
growth factor (EGF)) (7). Type II cysts have an electro-
lyte composition more similar to that found in plasma
(Na+/K+ ratio .3) and lower concentrations of sex
hormones and EGF (8).
Breast cysts are not considered pre-malignant
lesions. Several reports, however, have indicated that
bearers of cysts have a two- to fourfold higher risk of
later developing cancer (9, 10). It has been described
that the increased risk of breast cancer in women
with breast cysts seems to be concentrated among
women with type I breast cysts, with a relative risk of
4.2 (8). However, this last statement is still a matter
of controversy (7).
Insulin-like growth factor-I and -II (IGF-I and IGF-II)
are potent mitogens that play a pivotal role in regulat-
ing cell proliferation, differentiation and apoptosis. The
effects of IGFs are mediated through the IGF-I receptor,
which is also involved in cell transformation induced by
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tumor virus proteins and oncogene products (11). Six
IGF-binding proteins (IGFBPs) can inhibit or enhance
the actions of IGFs (12).
Epidemiological studies have found that high levels
of circulating IGF-I and low levels of IGFBP-3 are
associated with increased risk of breast cancer,
suggesting a possible involvement of IGF-I and IGFBP-
3 in the development of the disease (13, 14). Other
authors found this difference only in pre-menopausal
women (15, 16). Nevertheless, two other reports
showed no significant differences in either IGF-I or
IGFBP-3, but these groups compared breast cancer
patients with women with benign disease of the
breast (17, 18). However, the possibility of altered
values of IGF-I or IGFBP-3 in patients with benign
disease cannot be discounted. Recently, two prospective
epidemiological studies described an enhancement in
circulating IGF-I, relating it to the risk of developing
breast cancer in pre-menopausal women (19, 20).
Very recently, another study described a similar associ-
ation between free IGF-I levels and breast cancer (21).
The present data describe enhanced serum levels of
bioavailable IGF-I, due to lower levels of IGFBP-1 and
IGFBP-3 in patients with type I breast cysts. The
levels found in these patients are similar to those
described in the literature for women who develop
breast cancer later in their lives.
Subjects and methods
Subjects
Seventy pre-menopausal women were studied. Forty-five
of them were diagnosed as patients with GCD, classified
according to Haagensen’s criterion (cyst greater than
3 mm in diameter, as measured by ultrasound) (1).
The other 25 women were healthy and fulfilled the
necessary requirements to be controls: similar age
range, BMI and menstrual cycle characteristics (Table 1).
Patients were analyzed because of a breast lump
found by auto-examination, or clinical examination.
All the patients were subjected to a physical examin-
ation, mammography, ultrasonic examination and
fine-needle aspiration and cytology of the material aspi-
rated. The cysts were aspirated only when the ultra-
sound diameter was greater than 3 mm, either in the
case of a single or multiple cysts. Cysts were aspirated
for therapeutic reasons, as indicated by clinical consen-
sus (22). The patients did not present a family history of
breast cancer.
Control women did not present cysts, as ruled out by
physical examination, mammography and ultrasound,
and did not present any family history of breast cancer.
From the 45 patients with GCD, 31 presented a
single cyst, four presented double cysts, and ten pre-
sented more than three cysts simultaneously. All the
patients showed cysts greater than 3 mm, and they
were then all aspirated at least once. Only three
patients recurred and none developed breast cancer
during the study.
Patients were classified as possessing a type I cyst
when the Na+/K+ ratio in the BCF was ,3, and type
II in the opposite case. The majority of the patients
with multiple cysts (10/14) presented the same kind
of cyst, and the four patients that presented mixed
cysts were excluded. Post-menopausal women, patients
with either endocrine pathologies or breast cancer and
pregnant women were also excluded from the study.
Therefore all patients and controls were menstruating
regularly, and none of them had used oral contracep-
tives in the 6 months prior to the study. A pre-meno-
pausal woman was defined as a female who had
regular menstrual periods 3 months before entering
the study and had adequate levels of estradiol and gon-
adotropins. Women with ovulatory biphasic cycles
were defined by serum progesterone concentrations
.2.5 ng/ml during the luteal phase (LPh, between
days 20 and 23). When serum progesterone concen-
trations were ,2.5 ng/ml during days 20–23, the
cycle was considered monophasic. The percentage of
women with undetermined monophasic cycles was
around 25% in both healthy women and patients.
This percentage is adequate for peri-menopausal
women who have a higher frequency of anovulation
compared with younger women with a normal men-
strual cycle (23).
Both patients and controls were examined in two
medical centers by two different well trained ultrasound
observers.
BCF aspiration was performed during the early fol-
licular phase of the menstrual cycle (FPh, between
days 3 and 7) with blood extraction at early FPh
and LPh.
The protocol was approved by two local Ethics Com-
mittees (Hospital Alema´n and Instituto de Biologı´a y
Medicina Experimental) according to the Helsinki II
Declaration.
Methods
Assays A fasting blood sample was obtained from each
subject between 0830 and 1100 h, serum collected and
stored at 220 8C until assayed. All samples from an
individual woman were analyzed in duplicate in the
same assay for each hormone.
Table 1 Characteristics of controls and patients.
Controls GCD P value; significance
N 25 45
Age (years) 43.5^3.7 44.6^4.8 0.289; NS
BMI (kg/m2) 22.8^2.6 22.9^4.2 0.918; NS
Biphasic cycles 72% 69% 0.785; NS
Monophasic cycles 28% 31% 0.785; NS
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Sex steroids and gonadotropins were studied in order
to establish menstrual characteristics. Estradiol and pro-
gesterone were measured by RIA (Diagnostic System
Laboratories, Inc., Webster, TX, USA). The assay sensi-
tivities were 4.7 pg/ml and 0.1 ng/ml respectively,
intra-assay coefficients of variation (CVs) were 5.3%
and 5.6%, and interassay CVs were 9.3% and 10.2%.
Serum luteinizing hormone (LH) and follicle-stimu-
lating hormone (FSH) measurements were done by
chemiluminescence (IMMULITE, Diagnostic Products
Corporation, LA, USA). The assay sensitivities were
0.7 mUI/ml and 0.1 mUI/ml respectively, intra-assay
CVs were 4.8% and 6.1% respectively, and interassay
CVs were 10.6% and 6.5% respectively for the range
of values measured.
IGF-I was determined in serum by IRMA after separ-
ation of IGFs from IGFBPs by acid –ethanol extraction
(Diagnostic System Laboratories, Inc.). The detection
limit was 0.80 ng/ml, intra-assay CV (measured in our
own hands) was 4.4% and interassay CV was 6.5%.
Total IGFBP-3 and IGFBP-1 levels were assayed using
IRMA assay kits supplied by Diagnostic System Labora-
tories, Inc. Reported intra-assay CVs were 2.7 –5.2% for
IGFBP-1 and 1.8 –3.9% for IGFBP-3; interassay CVs
were 3.5 –6.0% and 0.5 –1.9% respectively.
Na+ and K+ concentrations in BCF were measured by
flame spectrophotometry (EEL Flame Photometer) at
dilutions 1:100 and 1:500 respectively.
Statistical analysis
Since IGF-I, IGFBP-1 and IGFBP-3 concentrations are
widely dispersed, non-parametric statistical methods
were used. Kruskal –Wallis test, followed by Dunn’s
test (24), was used to compare levels of these proteins
between groups. A Chi square test was performed in
order to evaluate the proportion of cases and controls
with IGF , 207 ng/ml (19). Fisher’s Exact test was
used to evaluate the monophasic/biphasic menstrual
cycle, an unpaired t-test was used for comparing age
and BMI between controls and patients, and Spear-
man’s rank correlation was used to correlate IGF-I
concentrations with both binding proteins and with
estradiol concentration in the FPh (24). A difference
was considered significant when P , 0.05.
Results
Serum IGF-I concentrations for 25 healthy women and
41 patients bearing a single type of breast cyst were
measured. As summarized in Fig. 1, these results
were significantly different when patients with type I
cysts were compared with type II cyst. The percentage
of patients with serum IGF-I levels higher than
207 ng/ml, the cut-off value described by Hankinson
et al. (19) as the predictive concentration for increased
risk of breast cancer, was also significantly higher in
patients with type I cysts when compared with type II
using the Chi square test.
As the major IGF-binding protein is type 3, its con-
centration was measured in these serum samples.
Fig. 2 (top panel) depicts this concentration, showing
a highly significant decrease in patients with type I
cysts with respect to controls. In this case, no signifi-
cant difference was found between the different cyst
Figure 1 Serum IGF-I concentrations in controls (B; n ¼ 25) and patients with type I (W; n ¼ 24) and type II (X; n ¼ 17) cysts. The
numerical values are the median and range of each group. Statistical analysis was performed using the Kruskal–Wallis test, followed
by Dunn’s test. The dotted line indicates the cut-off value described by Hankinson et al. (19).
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types. As the IGF-I/IGFBP-3 ratio is an estimate
of free and biologically active IGF-I, we expressed the
results previously shown as this ratio (Fig. 2, bottom
panel). As can be seen in this figure, this ratio was
very significantly higher in patients with type I cysts
than both type II and healthy control patients. As has
already been described by several groups, the IGFBP-3
concentration correlated significantly with IGF-I levels
in controls ðr ¼ 0:562; P , 0:003Þ: This correlation
was also found in patients with GCD ðr ¼ 0:533;
P , 0:001Þ: We were also interested in determining
the IGFBP-1 concentration and its calculated ratio to
IGF-I due to the fact that this binding protein is not
directly regulated by the same hormone that regulates
the growth factor. IGFBP-1 levels (Fig. 3, top panel)
were significantly lower in patients with type I cysts
than with type II cysts. In addition, IGFBP-1 levels do
not correlate with IGF-I concentrations in controls
(r ¼ 20:027; NS) or in patients with GCD
(r ¼ 20:088; NS) (data not shown). The IGF-I/
IGFBP-1 ratio, depicted in Fig. 3, bottom panel, was sig-
nificantly higher in patients with type I cysts than in
type II bearers.
Serum levels of estradiol during the FPh were analyzed
in serum from the healthy women and cyst patients.
Healthy women showed 39:2^5:1 pg=ml; the whole
Figure 2 Serum IGFBP-3 concentrations (top panel) and IGF-I/IGFBP-3 ratio (bottom panel) in controls (B) and patients with type I (W)
and type II (X) cysts. The numerical values are the median and range for each group. Statistical analysis was performed using the
Kruskal–Wallis test, followed by Dunn’s test.
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group of patients 42:2^3:8 pg=ml; type I bearers alone
46:6^5:6 pg=ml; and patients with type II cysts 35:6^
5:7 pg=ml: These values were not significantly different
in any case as analyzed using the Kruskal–Wallis non-
parametric test. As shown in Fig. 4, serum IGF-I levels
correlate with estradiol concentrations in both healthy
women (top panel) and patients (bottom panel).
Discussion
IGF-I is a systemic growth factor with potent mitogenic
and anti-apoptotic properties, which could influence
the proliferative behavior of normal breast cells. As
has already been stated, prospective epidemiological
studies have offered growing evidence that increased
concentrations of IGF-I in the circulation of pre-meno-
pausal women may be related to breast cancer risk.
Such an association may be even stronger when the
IGF-I/IGFBP-3 ratio is utilized as a measure of IGF-I
available for biological activity (19, 20). On the other
hand, some studies have found an association between
type I breast cysts and risk of breast cancer (8, 25). It
should be noted that breast cysts are not considered
to be pre-malignant lesions but simple markers of an
increased risk affecting the whole organ (8). Even if
the difference in cancer risk between cysts types is
not accepted by the whole scientific community (7),
we found it worth exploring the possibility that IGF-I
Figure 3 Serum IGFBP-1 concentrations (top panel) and IGF-I/IGFBP-1 ratio (bottom panel) in controls (B) and patients with type I (W)
and type II (X) cysts. The numerical values are the median and range for each group. Statistical analysis was performed using the
Kruskal–Wallis test, followed by Dunn’s test.
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and, especially, the IGF-I/IGFBP-3 ratio (which can be
interpreted as a measure of IGF-I bioavailability)
could be, at least in part, one of the causes of the
increased risk in breast cancer. We have consequently
analyzed serum levels of IGF-I and two of its binding
proteins in healthy women and patients with breast
cysts, a common benign disease in pre-menopausal
women.
Serum levels of IGF-I were measured in 41 patients
and 25 healthy women. Patients bearing type I cysts
showed higher levels of serum IGF-I than those with
type II cysts. To our knowledge, no data are available
in the literature related to serum IGF-I levels and the
Na+/K+ ratio in cysts. Bearing in mind the possibility
of an association of cyst patients in general with an
increased risk of breast cancer, and the increase in
serum IGF-I levels several years before the appearance
of cancer, these results failed to show an association
between these two observations. However, a non-sig-
nificant increase was found in these levels when the
whole group of patients and controls were compared,
or when type I bearers were compared with controls.
Yet, the significant difference in serum IGF-I levels
between the different cyst types was an interesting find-
ing. In the Nurses Health Study, Hankinson et al. (19)
established a cut-off value of 207 ng/ml to discriminate
relative risk of breast cancer. These authors have estab-
lished tertiles instead of quintiles for IGF-I serum values
in their pre-menopausal controls because of the smaller
numbers. The cut-off value chosen discriminates
between the top vs medium and bottom tertiles in
pre-menopausal controls. In the present analysis, we
used the same kit as Hankinson’s group for measuring
IGF-I and IGFBP-3. Our cohort of controls was not large
enough to establish our own cut-off value. Neverthe-
less, the median value for the determinations of con-
trols by Hankinson’s group (19) was similar to ours
(169.0 vs 175 for controls). Choosing this cut-off
value, we calculated the proportion of controls and
patients of each group above and below it. A significant
difference was found by the Chi square test in the pro-
portion of controls and patients with type I with values
above and below the cut-off.
IGFBP-3 is the most abundant IGFBP in postnatal
serum, existing at levels an order of magnitude higher
than other IGFBPs. IGFBP-3 does not change acutely
(26). Type I patients showed lower IGFBP-3 levels
than controls. Type II patients exhibited intermediate
levels not significantly different from either controls
or type I cysts. The IGF-I/IGFBP-3 ratio was markedly
discriminatory between the study groups, showing sig-
nificant differences between type I vs control group and
type I vs type II patients. This result is the most relevant
finding in this study, since it can be interpreted as a
measurement of IGF-I bioavailability. The lower levels
of IGFBP-3 found in type I cyst patients should not be
interpreted as an alteration of the regulation by GH,
since IGF-I concentration correlated with IGFBP-3 in
a similar manner to controls. This correlation in
healthy women confirms previous results (27, 28).
IGFBP-1 was chosen as another IGFBP due to its
different regulation with respect to IGFBP-3. Although
some cytokines can stimulate IGFBP-1 in vitro and in
vivo, serum IGFBP-1 levels are predominantly regulated
by insulin and cortisol levels through transcriptional
control of hepatic IGFBP-1 synthesis (26). IGFBP-1
showed diminished levels in type I patients with respect
to type II bearers. An analysis of the IGF-I/IGFBP-1
ratio showed a similar pattern to that of the IGF-
I/IGFBP-3 ratio, although the amount of IGF-I bound
to IGFBP-1 is considerably lower. In adults, it has
been reported that there is a substantial genetic contri-
bution responsible for inter-individual variation of the
circulating levels of IGF-I and IGFBP-3, whereas no sig-
nificant heritability was found for IGFBP-1 concen-
trations (29, 30).
Some interactions between IGF-I and estrogen have
been described by other groups. In breast cancer
cells, estrogens enhance the mitogenic effect of IGF-I,
Figure 4 Correlation between serum IGF-I and estradiol (E2) con-
centrations during the FPh in healthy women (top panel) and
patients (bottom panel). The data were analyzed using Spear-
man’s rank correlation.
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induce expression of IGF-I, and stimulate production of
IGF-I receptors (11). Tamoxifen, which is anti-estro-
genic in breast tissue, abolishes the effects of estrogens
on IGF-I, inhibits transcription of IGF-I, and attenuates
the response of the IGF-I receptor (11). In contrast to
other reports, recent analysis using longitudinal
(within-subject) comparisons in the same menstrual
cycle, further disclosed that plasma IGF-I concen-
trations rise concomitantly in the pre-ovulatory phase
with the serum estradiol zenith (31). Serum estrogen
levels were then measured for controls and patients.
No significant differences were observed when controls
were compared with both the whole group of patients
or either cyst type bearers. On the other hand, IGF-I
concentrations were correlated significantly with estra-
diol during the FPh in both controls and patients. As
estrogen levels were similar in each group, the differ-
ences found in the IGF-I/IGFBP-3 system could not be
ascribed to estrogen action.
Women with biphasic cycles showed a higher fre-
quency of type I cysts (73%) whereas women with
monophasic cycles had a higher frequency of type II
cysts (60%), as analyzed by Fisher’s exact test. This
fact could suggest that serum progesterone levels
could be related to cyst type.
Only three patients recurred during the study. This
fact precludes correlations between outcome and
IGF-I or IGF-I/IGFBP-3 values. No case of breast
cancer was found in the patients after the cysts were
aspired. However, in the future, these patients will be
followed in order to analyze these possibilities.
The present results show a clear and very significant
enhancement of serum IGF-I/IGFBP-3 ratio in patients
with type I cysts as compared with both controls and
type II cyst-bearers. It might be considered that the
up to sevenfold increase in breast cancer risk among
pre-menopausal women – #50 years old – suggests
that the relation between IGF-I and risk of breast
cancer may be greater than that of other established
breast cancer risk factors, with the exception of a
strong family history of breast cancer or a high density
mammographic profile (19). As breast cysts are not
pre-neoplasic lesions, certain factors – such as hor-
mones and growth factors, most probably – could be
related to the described enhanced risk of breast
cancer in breast cyst patients, especially those with
type I cysts. Therefore, it could be speculated that the
elevation of IGF-I bioavailability in type I cyst bearers
could eventually enhance breast cancer risk, probably
stimulating proliferation of the terminal duct lobular
units of the breast, the site of origin of both breast
cysts and breast cancer.
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